Idarucizumab for Dabigatran Reversal — Full Cohort AnalysisCharles V. Pollack, Jeffrey I. Weitz, Frank W. Sellke et al.|New England Journal of Medicine|2017Cited by 1.1k
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatranPaul A. Reilly, Charles V. Pollack, Richard A. Bernstein et al.|Thrombosis and Haemostasis|2015Cited by 154
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ studyCharles V. Pollack, Jeffrey I. Weitz, Richard A. Bernstein et al.|Journal of Medical Economics|2016Cited by 11
INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY OR INTERVENTIONSCharles V. Pollack, CW Kam, John W. Eikelboom et al.|Emergency Medicine Journal|2015Cited by 7
Abstract 16418: Reinitiation of Antithrombotic Therapy After Emergency Procedures or After an Uncontrolled or Life Threatening Bleeding Event. Initial Experience From the Re-verse Ad TrialCharles V. Pollack, Jeffrey I. Weitz, Paul Reilly et al.|Circulation|2015Cited by 5